Skip to main content

Advertisement

Log in

Opinion statement

  • There have been numerous reports stating that treatment of acute rheumatic fever with either aspirin or corticosteroids does not alter the long-term outcome of rheumatic heart disease. Yet, it should be emphasized that most of these studies were carried out with the first generic corticosteroids before the advent of the more active and more potent corticosteroid agents. In spite of this caveat, there is no question that all the clinical and laboratory parameters of inflammation (erythrocyte sedimentation rate, C-reactive protein) return to normal much more rapidly with corticosteroids than with aspirin alone. It is therefore our belief that steroids should be used when clinical and laboratory evidence of carditis exists, and aspirin should be reserved for cases of acute rheumatic arthritis with no evidence of carditis.

  • The incidence of long-term valvular disease in active carditis may be decreased with steroid therapy. For example, the number of valve replacements differs markedly in centers that do use steroids and in those that do not. In Capetown, South Africa, where steroids are routinely used for carditis, valve replacement is quite rare. In contrast, in Johannesburg, where steroids are rarely used, the rate of valve replacement is quite high. The racial backgrounds of both groups of patients are similar, thus eliminating the question of racial differences.

  • Concerning secondary prophylaxis, there is also controversy concerning the best second-line therapy. It is now well known that monthly intramuscular injections of benzathine penicillin are really effective for only 20 days. Thus, there is a window in which penicillin coverage is not adequate. To circumvent this problem, some investigators give benzathine penicillin every 3 weeks. These injections are quite painful, however, and it has been our “rule” that compliance with this treatment is inversely proportional to the ratio of the size of the child to the mother.

  • In our own experience over 30 years with the follow-up of more than 300 patients with acute rheumatic fever, careful discussion of the consequences of missing oral doses has been adequate to insure proper compliance. An analysis of our patients on oral penicillin prophylaxis compared with other groups using benzathine penicillin revealed that there was very little difference in recurrence rate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Dajani AS, Taubert KA, Takahashi M, et al.: Guidelines for the management of patients with rheumatic fever. Report of the Council on Cardiovascular Disease in the Young of the American Heart Association. Circulation 1994, 89:916–922.

    PubMed  CAS  Google Scholar 

  2. Bessen D, Jones KF, Fischetti VA: Evidence for two distinct classes of streptococcal M protein and their relationship to rheumatic fever. J Exp Med 1989, 169:269–283.

    Article  PubMed  CAS  Google Scholar 

  3. Denny FW, Wannamaker LW, Brink WR, et al.: Prevention of rheumatic fever. Treatment of the preceding streptococcal infection. JAMA 1950, 143:151–153.

    CAS  Google Scholar 

  4. Stollerman GH: Changing streptococci and prospects for the global eradication of rheumatic fever. Perspect Biol Med 1997, 40:165–189. Very comprehensive review of rheumatic fever and its treatment.

    PubMed  CAS  Google Scholar 

  5. Snitcowsky R: Rheumatic fever prevention in industrializing countries: problems and approaches. Pediatrics 1996, 97:996–998. Reviews prophylaxis for rheumatic fever in developing countries.

    PubMed  CAS  Google Scholar 

  6. Berrios X, del Campo E, Guzman B, et al.: Discontinuing rheumatic fever prophylaxis in selected adolescents and young adults. A prospective study [see comments]. Ann Intern Med 1993, 118:401–406.

    PubMed  CAS  Google Scholar 

  7. Albert DA, Harel L, Karrison T: The treatment of rheumatic carditis: a review and meta-analysis. Medicine (Baltimore) 1995, 74:1–12.

    Article  CAS  Google Scholar 

  8. Stollerman GH: Rheumatic carditis. Lancet 1995, 346:390–392.

    Article  PubMed  CAS  Google Scholar 

  9. Currie BJ: Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever? Pediatrics 1996, 97:989–991. Small Australian study reviewing different regimens of intramuscular penicillin for secondary prophylaxis.

    PubMed  CAS  Google Scholar 

  10. Hench PS, Slocomb CH, Barnes AR, et al.: The effects of adrenal cortical hormone 17-hydroxy-11-dehydrocorticosterone (compound E) on acute phase of rheumatic fever. Preliminary report. Mayo Clin Proc 1949, 24:277–297.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Visvanathan, K., Manjarez, R.C. & Zabriskie, J.B. Rheumatic fever. Curr Treat Options Cardio Med 1, 253–258 (1999). https://doi.org/10.1007/s11936-999-0041-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-999-0041-5

Keywords

Navigation